Metacrine Announces Date of Fourth Quarter and Full Year 2020 Financial Results Conference Call
March 11 2021 - 6:15AM
Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical
company focused on discovering and developing differentiated
therapies for patients with liver and gastrointestinal diseases,
today announced that management will host a conference call and
webcast to discuss its fourth quarter and full year 2020 financial
results and other business highlights on Thursday, March 18, 2021
at 8:30 a.m. ET.
To participate in the conference call, please dial (833)
614-1526 (domestic) or (520) 809-9922 (international) and refer to
conference ID 4995715. A webcast will be available in the investor
section of the company's website at www.metacrine.com, and will be
archived for 60 days following the call.
About MetacrineMetacrine, Inc. (Nasdaq: MTCR)
is a clinical-stage biopharmaceutical company building a
differentiated pipeline of therapies to treat liver and
gastrointestinal (GI) diseases. Metacrine has developed a
proprietary farnesoid X receptor (FXR) platform utilizing a unique
chemical scaffold, which has demonstrated a differentiated and
improved therapeutic profile in clinical trials. The company’s two
product candidates, MET409 and MET642, are currently being
investigated in clinical trials as potential new treatments for
non-alcoholic steatohepatitis (NASH). MET409 has completed a
12-week monotherapy trial in patients with NASH and is being
evaluated in a 12-week combination trial with empagliflozin in
patients with both NASH and type 2 diabetes. MET642 has completed a
14-day Phase 1 trial in healthy volunteers and is being evaluated
in a 16-week monotherapy trial in patients with NASH.
Contact:Steve
Kunszaboinvestors@metacrine.com
Metacrine (NASDAQ:MTCR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Metacrine (NASDAQ:MTCR)
Historical Stock Chart
From Apr 2023 to Apr 2024